Published in Cancer Biol Ther on October 13, 2007
Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol (2013) 1.16
Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic. Prog Mol Biol Transl Sci (2010) 1.14
Parathyroid hormone-related protein: an update. J Clin Endocrinol Metab (2012) 1.13
Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostin. Breast Cancer Res (2011) 1.05
Membrane lipids in invadopodia and podosomes: key structures for cancer invasion and metastasis. Oncotarget (2010) 1.00
Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-α36 (ERα36). J Biol Chem (2012) 0.99
TGFβ-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential. Cancer Biol Ther (2011) 0.99
Integrin αvβ6 promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Res (2014) 0.97
A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy. Cancer Gene Ther (2009) 0.95
Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Hum Gene Ther (2010) 0.94
Parathyroid hormone-related protein is not required for normal ductal or alveolar development in the post-natal mammary gland. PLoS One (2011) 0.92
Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host. Cancer Gene Ther (2012) 0.92
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer. Mol Ther (2011) 0.89
The calcium-sensing receptor in the breast. Best Pract Res Clin Endocrinol Metab (2013) 0.85
Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol (2011) 0.85
Lectin RCA-I specifically binds to metastasis-associated cell surface glycans in triple-negative breast cancer. Breast Cancer Res (2015) 0.84
Optimal management of bone metastases in breast cancer patients. Breast Cancer (Dove Med Press) (2011) 0.83
Systemic Delivery of an Oncolytic Adenovirus Expressing Decorin for the Treatment of Breast Cancer Bone Metastases. Hum Gene Ther (2015) 0.83
PTHrP and breast cancer: more than hypercalcemia and bone metastases. Breast Cancer Res (2012) 0.82
Role of bone-anabolic agents in the treatment of breast cancer bone metastases. Breast Cancer Res (2014) 0.82
Mechanisms involved in breast cancer liver metastasis. J Transl Med (2015) 0.82
A Review of the Clinical Implications of Breast Cancer Biology. Electron Physician (2016) 0.82
Breast cancer at bone metastatic sites: recent discoveries and treatment targets. J Cell Commun Signal (2011) 0.81
Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells. Clin Exp Metastasis (2014) 0.80
Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: Osteolytic versus osteoblastic. Surg Neurol Int (2016) 0.79
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res (2016) 0.77
NF-κB signaling regulates cell-autonomous regulation of CXCL10 in breast cancer 4T1 cells. Exp Mol Med (2017) 0.75
Calcium-Sensing Receptor in Breast Physiology and Cancer. Front Physiol (2016) 0.75
Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget (2017) 0.75
Functional osteoclastogenesis: the baseline variability in blood donor precursors is not associated with age and gender. Oncotarget (2015) 0.75
The role of osteoblasts in bone metastasis. J Bone Oncol (2016) 0.75
Potential suppressive effects of gentian violet on human breast cancer MDA-MB-231 cells in vitro: Comparison with gemcitabine. Oncol Lett (2016) 0.75
Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy. Oncotarget (2016) 0.75
Co-expression of parathyroid hormone related protein and TGF-beta in breast cancer predicts poor survival outcome. BMC Cancer (2015) 0.75
What Is Breast in the Bone? Int J Mol Sci (2016) 0.75
A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support Care Cancer (2014) 0.75
The release of inflammatory cytokines from human peripheral blood mononuclear cells in vitro following exposure to adenovirus variants and capsid. Hum Gene Ther (2002) 1.24
Targeting TGFbeta signaling for cancer therapy. Cancer Biol Ther (2005) 1.12
TGFβ-dependent induction of interleukin-11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential. Cancer Biol Ther (2011) 0.99
Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-β inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther (2012) 0.96
Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther (2002) 0.94
Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II. Cancer Immunol Immunother (2002) 0.94
Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Hum Gene Ther (2010) 0.94
Adenoviral delivery of p53 gene suppresses expression of collagenase-3 (MMP-13) in squamous carcinoma cells. Oncogene (2002) 0.93
Oncolytic adenovirus expressing soluble TGFβ receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer. Mol Ther (2011) 0.89
Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model. Hum Gene Ther (2011) 0.88
MicroRNA regulation of oncolytic adenovirus 6 for selective treatment of castration-resistant prostate cancer. Mol Cancer Ther (2012) 0.83
Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc). Cancer Gene Ther (2002) 0.83
An oncolytic adenovirus expressing soluble transforming growth factor-beta type II receptor for targeting breast cancer: in vitro evaluation. Mol Cancer Ther (2006) 0.83
Rat sodium iodide symporter for radioiodide therapy of cancer. Clin Cancer Res (2004) 0.81
Prolonged adenovirus-mediated expression of p27(Kip1) unveils unexpected effects of this protein on the phenotype of SUDHL-1 cells derived from t(2;5)-anaplastic large cell lymphoma. Leuk Res (2003) 0.77
Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p16INK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin's disease. Leuk Lymphoma (2002) 0.76
Adenovirus expressing p27KIP1 induces apoptosis against cholangiocarcinoma cells by triggering Fas ligand on the cell surface. Hepatogastroenterology (2003) 0.76
Evaluating apoptosis in tumor cells infected with adenovirus expressing p53 tumor suppressor gene. Methods Mol Med (2007) 0.75